Clinical trial results:
The role of paroxetine in patients taking telaprevir-based HCV therapy: lack of a drug-drug interaction? (ROLEX)

Summary

EudraCT number	2012-005372-34
Trial protocol	NL
Global end of trial date	15 September 2014

Results information

Result version number	v1 (current)
This version publication date	21 September 2019
First version publication date	21 September 2019

Trial information

Trial identification

Sponsor protocol code	UMCN-AKF12.02

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Radboudumc
Sponsor organisation address	Geert Grooteplein Zuid 10, Nijmegen, Netherlands,
Public contact	David Burger, Radboud University Medical Centre, 31 243616405,
Scientific contact	David Burger, Radboud University Medical Centre, 31 243616405,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 September 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 September 2014
Global end of trial reached?	Yes
Global end of trial date	15 September 2014
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To show that concomitant use of telaprevir (1125 mg BID) does not lead to a relevant decrease (> 20%) in the paroxetine parameter AUC0-24h compared to paroxetine alone.

Protection of trial subjects:

The study will be performed in HCV infected patients who will be treated with telaprevir containing HCV treatment. Patients are already on antidepressant therapy with paroxetine. We chose to conduct this study in this population because these patients will be treated with telaprevir and paroxetine anyway and will be exposed to these drugs in regular care. The burden of participation in the trial is limited. We only perform a minimal change in the standard treatment regimen, since included patients are already on antidepressant thera-py with paroxetine and are eligible for start of a TVR-containing regimen for treatment of their HCV infection. To further limit the burden, study visits are mostly planned in accord-ance with the regular visiting scheme for HCV treatment.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 April 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 3
Worldwide total number of subjects	3
EEA total number of subjects	3

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	3

From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

At least 18 and not older than 65 years at screening, able and willing to sign the Informed Consent Form prior to screening evaluations, subject has a chronic HCV infection with genotype 1, subject is eligible for telaprevir containing HCV treatment, subject is on a stable dose of 20 mg paroxetine QD for at least 4 weeks.

Period 1

Period 1 title	paroxetine alone
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	paroxetine
Arm description: -	
Arm type	Active comparator
Investigational medicinal product name	paroxetine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

20 mg once daily

Number of subjects in period 1	paroxetine
Started	3
Completed	2
Not completed	1
Physician decision	1

Period 2

Period 2 title	paroxetine + telaprevir
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	interaction arm
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	paroxetine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 20 mg once daily	
Investigational medicinal product name	telaprevir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 1125 mg twice daily	

Number of subjects in period 2	interaction arm
Started	2
Completed	2

Baseline characteristics

Reporting groups	
Reporting group title	paroxetine alone

Reporting group description: -

Reporting group values	paroxetine alone	Total	
Number of subjects	3	3	
Age categorical Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous Units: years			
median	44		
full range (min-max)	34 to 53	-	
Gender categorical Units: Subjects			
Female	1	1	
Male	2	2	

End points

End points reporting groups	
Reporting group title	paroxetine
Reporting group description: -	
Reporting group title	interaction arm
Reporting group description: -	

Primary: paroxetine AUC0-24h decrease	
End point title	paroxetine AUC0-24h decrease
End point description:	
To show that concomitant use of telaprevir (1125 mg BID) does not lead to a relevant decrease (> 20%) in the paroxetine parameter AUC0-24h compared to paroxetine alone.	
End point type	Primary
End point timeframe:	
Interaction versus paroxetine alone	

End point values	paroxetine	interaction arm		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	2		
Units: %	0	100		

Statistical analyses

Statistical analysis title	descriptive
Statistical analysis description:	
Individual analysis	
Comparison groups	paroxetine v interaction arm
Number of subjects included in analysis	4
Analysis specification	Pre-specified
Analysis type	other[1]
P-value	< 0.05
Method	ANOVA
Parameter estimate	geometric mean ratio
Confidence interval	
level	90 %
sides	2-sided
lower limit	0.8
upper limit	2
Variability estimate	Standard error of the mean

Notes:

[1] - explorative

Adverse events

Adverse events information[1]	
Timeframe for reporting adverse events: entire study	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	none
Dictionary version	1

Frequency threshold for reporting non-serious adverse events: 1 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: No (serious)adverse events were reported

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
15 September 2014	Telaprevir was not being used anymore end 2014, therefore no further inclusions were expected.	-

Notes:

Limitations and caveats

None reported